세계의 스마트 치료 기기 시장 규모, 점유율, 동향 분석 보고서 : 기기별, 유통별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Smart Therapeutic Devices Market Summary

The global smart therapeutic devices market size was estimated at USD 77.12 billion in 2024 and is projected to reach USD 159.42 billion by 2030, growing at a CAGR of 12.99% from 2025 to 2030. This growth is attributed to technological advancements, rising prevalence of chronic diseases, and the growing demand for personalized and home-based care.

This growth is attributed to technological advancements, rising prevalence of chronic diseases, and the growing demand for personalized and home-based care. Moreover, increasing adoption of portable and connected devices-such as insulin pumps, smart inhalers, and neurostimulation systems-has significantly enhanced disease management capabilities, particularly for conditions like diabetes, asthma, COPD, and neurological disorders. The integration of AI, data tracking, and wireless connectivity enables real-time monitoring, patient engagement, and clinical decision-making, thereby improving treatment outcomes and patient adherence.

With chronic disease management requiring continuous care, smart therapeutic devices bridge the gap between hospital visits and home-based healthcare, ultimately contributing to improved quality of life and reduced hospitalization rates. For instance, in July 2022, OMRON Healthcare launched a portable oxygen concentrator delivering 5L/min of >90% pure oxygen using PSA technology. Designed for home care, it features a compact, durable design with caster wheels for mobility.

Moreover, the trend toward personalized medicine continues to accelerate the adoption of smart technologies. For instance, in February 2024, Tandem Diabetes Care launched Tandem Mobi, the world's smallest durable automated insulin delivery system. This compact, wearable device offers full iOS mobile control, advanced Control-IQ technology, and compatibility with Dexcom CGMs, enabling personalized insulin therapy for users aged six and up.

According to the World Health Organization (WHO), as of 2024, noncommunicable diseases (NCDs) such as cardiovascular diseases, cancer, diabetes, and chronic respiratory conditions account for over 74% of global mortality annually. In response, the WHO is actively promoting greater investment in digital health solutions-including telemedicine and mobile health technologies-as a cost-effective strategy to manage and mitigate the impact of NCDs. Notably, an investment of merely USD 0.24 per patient per year in digital health interventions is projected to save over 2 million lives and prevent nearly 7 million acute events and hospitalizations over the next decade, thereby alleviating significant pressure on global healthcare systems.

These global imperatives are driving healthcare technology providers to expand and diversify their smart therapeutic device portfolios. A key example is GN's February 2025 launch of ReSound Vivia, touted as the world's smallest AI-powered hearing aid. Trained on 13.5 million real-world sentences, the device significantly enhances speech clarity in noisy environments while offering extended battery life of up to 30 hours for all-day use. GN also introduced ReSound Savi, a value-driven product line featuring Bluetooth LE Audio and Auracast broadcast capabilities-further democratizing access to advanced hearing solutions and aligning with global digital health priorities.

The COVID-19 pandemic significantly increased the demand for smart therapeutic devices like portable oxygen concentrators and ventilators became critical for managing respiratory complications. Smart inhalers, connected inhalers, and COPD management tools gained prominence due to the rise in respiratory illness awareness. On the other hand, insulin pumps, wearable injectors, and implantable drug delivery devices helped reduce hospital visits for chronic disease patients. The pandemic also pushed the adoption of neurostimulation and hearing devices through telehealth integration.

Global Smart Therapeutic Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global smart therapeutic devices market report based on devices, distribution, end use and regions.

• Devices Type Outlook (Revenue, USD Million, 2018 - 2030)
• Portable Oxygen Concentrators & Ventilators
• Insulin Pumps
• Hearing Aids
• Neurostimulation Devices
  • Spinal Cord Stimulation
  • Deep Brain Stimulation
  • Transcranial Magnetic Stimulation
• Smart Inhalers
  • Asthma & COPD Management
  • Connected Inhalers with Data Tracking
• Smart Drug Delivery Systems
  • Wearable Injectors
  • Implantable Drug Delivery Devices
• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
• Pharmacies
• Online Channel
• Direct-to-Consumer (DTC)
• Others (Hypermarkets, Specialty Retailers)
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Clinics
• Home Care
• Others (Sports, Fitness Centers, Assisted Living)
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapeutic Devices
  • 1.2.2. Device/Product
  • 1.2.3. Technology/Software
  • 1.2.4. Distribution
  • 1.2.5. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increase in personalized treatment plans
    • 3.2.1.2. Technological Advancements
    • 3.2.1.3. Rising Prevalence of Chronic Diseases
  • 3.2.2. Market Restraint Analysis
  • 3.2.3. Industry Opportunity Analysis
  • 3.2.4. Industry Challenge Analysis
  • 3.2.5. Case Studies
• 3.3. Business Environment Analysis
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
• 3.4. COVID 19 Impact Analysis

Chapter 4. Smart Therapeutics Devices Market: Therapeutic Devices Type Estimates & Trend Analysis

• 4.1. Therapeutic Devices Segment Dashboard
• 4.2. Therapeutic Devices Market Share Movement Analysis, 2024 & 2030
• 4.3. Market Size & Forecasts and Trend Analysis, by Devices Type, 2018 to 2030 (USD Million)
  • 4.3.1. Portable Oxygen Concentrators & Ventilators
    • 4.3.1.1. Portable Oxygen Concentrators & Ventilators market, 2018 - 2030 (USD Million)
  • 4.3.2. Insulin Pumps
    • 4.3.2.1. Insulin Pumps market, 2018 - 2030 (USD Million)
  • 4.3.3. Hearing Aids
    • 4.3.3.1. Hearing Aids market, 2018 - 2030 (USD Million)
  • 4.3.4. Neurostimulation Devices
    • 4.3.4.1. Neurostimulation Devices market, 2018 - 2030 (USD Million)
    • 4.3.4.2. Spinal Cord Stimulation
      • 4.3.4.2.1. Spinal Cord Stimulation market, 2018 - 2030 (USD Million)
    • 4.3.4.3. Deep Brain Stimulation
      • 4.3.4.3.1. Deep Brain Stimulation market, 2018 - 2030 (USD Million)
    • 4.3.4.4. Transcranial Magnetic Stimulation
      • 4.3.4.4.1. Transcranial Magnetic Stimulation market, 2018 - 2030 (USD Million)
  • 4.3.5. Smart Inhalers
    • 4.3.5.1. Smart Inhalers market, 2018 - 2030 (USD Million)
    • 4.3.5.2. Asthma & COPD Management
      • 4.3.5.2.1. Asthma & COPD Management market, 2018 - 2030 (USD Million)
    • 4.3.5.3. Connected Inhalers with Data Tracking
      • 4.3.5.3.1. Connected Inhalers with Data Tracking market, 2018 - 2030 (USD Million)
  • 4.3.6. Smart Drug Delivery Systems
    • 4.3.6.1. Smart Drug Delivery Systems market, 2018 - 2030 (USD Million)
    • 4.3.6.2. Wearable Injectors
      • 4.3.6.2.1. Wearable Injectors market, 2018 - 2030 (USD Million)
    • 4.3.6.3. Drug Delivery Devices
      • 4.3.6.3.1. Drug Delivery Devices market, 2018 - 2030 (USD Million)

Chapter 5. Smart Therapeutics Devices Market: Distribution Channel Estimates & Trend Analysis

• 5.1. Distribution Segment Dashboard
• 5.2. Distribution Market Share Movement Analysis, 2024 & 2030
• 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 5.4. Pharmacies
  • 5.4.1. Pharmacies market, 2018 - 2030 (USD Million)
• 5.5. Online Channel
  • 5.5.1. Online Channel market, 2018 - 2030 (USD Million)
• 5.6. Direct-to-Consumer (DTC)
  • 5.6.1. Direct-to-Consumer (DTC) market, 2018 - 2030 (USD Million)
• 5.7. Others (Hypermarkets, Specialty Retailers)
  • 5.7.1. Others (Hypermarkets, Specialty Retailers) market, 2018 - 2030 (USD Million)

Chapter 6. Smart Therapeutics Devices Market: End Use Estimates & Trend Analysis

• 6.1. End Use Segment Dashboard
• 6.2. End Use Market Share Movement Analysis, 2024 & 2030
• 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market, 2018 - 2030 (USD Million)
• 6.5. Clinics
  • 6.5.1. Clinics market, 2018 - 2030 (USD Million)
• 6.6. Home Care
  • 6.6.1. Home Care market, 2018 - 2030 (USD Million)
• 6.7. Others (Sports, Fitness Centers, Assisted Living)
  • 6.7.1. Others (Sports, Fitness Centers, Assisted Living) market, 2018 - 2030 (USD Million)

Chapter 7. Smart Therapeutics Devices Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market: Key Takeaways
• 7.3. North America
  • 7.3.1. North America smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamic
    • 7.3.2.2. Regulatory framework
    • 7.3.2.3. Competitive insights
    • 7.3.2.4. U.S. smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamic
    • 7.3.3.2. Regulatory framework
    • 7.3.3.3. Competitive insights
    • 7.3.3.4. Canada smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamic
    • 7.3.4.2. Regulatory framework
    • 7.3.4.3. Competitive insights
    • 7.3.4.4. Mexico smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamic
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Competitive insights
    • 7.4.2.4. Germany smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. UK
    • 7.4.3.1. Key country dynamic
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Competitive insights
    • 7.4.3.4. UK smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamic
    • 7.4.4.2. Regulatory framework
    • 7.4.4.3. Competitive insights
    • 7.4.4.4. France smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamic
    • 7.4.5.2. Regulatory framework
    • 7.4.5.3. Competitive insights
    • 7.4.5.4. Italy smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamic
    • 7.4.6.2. Regulatory framework
    • 7.4.6.3. Competitive insights
    • 7.4.6.4. Spain smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key country dynamic
    • 7.4.7.2. Regulatory framework
    • 7.4.7.3. Competitive insights
    • 7.4.7.4. Denmark smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key country dynamic
    • 7.4.8.2. Regulatory framework
    • 7.4.8.3. Competitive insights
    • 7.4.8.4. Sweden smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key country dynamic
    • 7.4.9.2. Regulatory framework
    • 7.4.9.3. Competitive insights
    • 7.4.9.4. Norway smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key country dynamic
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive insights
    • 7.5.2.4. Japan smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key country dynamic
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive insights
    • 7.5.3.4. China smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamic
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive insights
    • 7.5.4.4. India smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamic
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Competitive insights
    • 7.5.5.4. South Korea smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Australia
    • 7.5.6.1. Key country dynamic
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Competitive insights
    • 7.5.6.4. Australia smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamic
    • 7.5.7.2. Regulatory framework
    • 7.5.7.3. Competitive insights
    • 7.5.7.4. Thailand smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America smart therapeutics devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamic
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive insights
    • 7.6.2.4. Brazil smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamic
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive insights
    • 7.6.3.4. Argentina smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamic
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive insights
    • 7.7.2.4. South Africa smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamic
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive insights
    • 7.7.3.4. Saudi smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamic
    • 7.7.4.2. Regulatory framework
    • 7.7.4.3. Competitive insights
    • 7.7.4.4. UAE smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamic
    • 7.7.5.2. Regulatory framework
    • 7.7.5.3. Competitive insights
    • 7.7.5.4. Kuwait smart therapeutics devices market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Inogen, Inc.
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial performance
    • 8.5.1.3. Product benchmarking
    • 8.5.1.4. Strategic initiatives
  • 8.5.2. Presspart Verwaltungs GmbH.
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial performance
    • 8.5.2.3. Product benchmarking
    • 8.5.2.4. Strategic initiatives
  • 8.5.3. Cognita Labs
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial performance
    • 8.5.3.3. Product benchmarking
    • 8.5.3.4. Strategic initiatives
  • 8.5.4. adherium
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial performance
    • 8.5.4.3. Product benchmarking
    • 8.5.4.4. Strategic initiatives
  • 8.5.5. Medtronic
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial performance
    • 8.5.5.3. Product benchmarking
    • 8.5.5.4. Strategic initiatives
  • 8.5.6. Hoffmann-La Roche AG
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial performance
    • 8.5.6.3. Product benchmarking
    • 8.5.6.4. Strategic initiatives
  • 8.5.7. Insulet Corporation
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. Audicus
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product benchmarking
    • 8.5.8.4. Strategic initiatives
  • 8.5.9. Eargo, Inc.
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial performance
    • 8.5.9.3. Products & Services benchmarking
    • 8.5.9.4. Strategic initiatives
  • 8.5.10. Nidek Medical Products, Inc.
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial performance
    • 8.5.10.3. Product benchmarking
    • 8.5.10.4. Strategic initiatives
  • 8.5.11. Koninklijke Philips N.V.
    • 8.5.11.1. Overview
    • 8.5.11.2. Financial performance
    • 8.5.11.3. Product benchmarking
    • 8.5.11.4. Strategic initiatives
  • 8.5.12. Drive Devilbiss International
    • 8.5.12.1. Overview
    • 8.5.12.2. Financial performance
    • 8.5.12.3. Product benchmarking
    • 8.5.12.4. Strategic initiatives
  • 8.5.13. Tandem Diabetes Care, Inc.
    • 8.5.13.1. Overview
    • 8.5.13.2. Financial performance
    • 8.5.13.3. Product benchmarking
    • 8.5.13.4. Strategic initiatives
  • 8.5.14. Ypsomed
    • 8.5.14.1. Overview
    • 8.5.14.2. Financial performance
    • 8.5.14.3. Product benchmarking
    • 8.5.14.4. Strategic initiatives
  • 8.5.15. GN Hearing
    • 8.5.15.1. Overview
    • 8.5.15.2. Financial performance
    • 8.5.15.3. Product benchmarking
    • 8.5.15.4. Strategic initiatives
  • 8.5.16. Cochlear Ltd.
    • 8.5.16.1. Overview
    • 8.5.16.2. Financial performance
    • 8.5.16.3. Product benchmarking
    • 8.5.16.4. Strategic initiatives
  • 8.5.17. Sonova.
    • 8.5.17.1. Overview
    • 8.5.17.2. Financial performance
    • 8.5.17.3. Product benchmarking
    • 8.5.17.4. Strategic initiatives
  • 8.5.18. Boston Scientific Corporation
    • 8.5.18.1. Overview
    • 8.5.18.2. Financial performance
    • 8.5.18.3. Product benchmarking
    • 8.5.18.4. Strategic initiatives
  • 8.5.19. Abbott.
    • 8.5.19.1. Overview
    • 8.5.19.2. Financial performance
    • 8.5.19.3. Product benchmarking
    • 8.5.19.4. Strategic initiatives
  • 8.5.20. Nevro Corp.
    • 8.5.20.1. Overview
    • 8.5.20.2. Financial performance
    • 8.5.20.3. Product benchmarking
    • 8.5.20.4. Strategic initiatives